Skip to main content
Finanzoo GmbH Finanzoo GmbH

Array BioPharma Value Stock - Dividend - Research Selection

Array biopharma

ISIN: US04269X1054 , WKN: 580564
Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.


Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet

Description of the company

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company\'s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,

NEWS


Deutsche Bank Starts Covering Array Technologies, Inc. (ARRY) with Buy Rating and $11 Price Target

2025-10-01
With strong hedge fund backing and favorable analyst ratings, Array Technologies, Inc. (NASDAQ:ARRY), makes our list of the 10 Most Promising Green Stocks According to Wall Street Analysts. On September 30, 2025, the $1.4 billion solar tracking technology company Array Technologies, Inc. (NASDAQ:ARRY) is receiving more attention now that Deutsche Bank started covering it with […]
Yahoo

Array (ARRY) Shares Skyrocket, What You Need To Know

2025-10-01
Shares of solar tracking systems manufacturer Array (NASDAQ:ARRY) jumped 10.3% in the afternoon session after the stock's positive momentum continued as analysts at both Baird and Deutsche Bank initiated coverage on the stock with favorable ratings. Baird assigned an "Outperform" rating, while Deutsche Bank started its coverage with a "Buy" rating, with both firms setting a price target of $11. In its analysis, Baird noted that the solar tracker maker stands to benefit from U.S. policy clarity a
Yahoo

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

2025-10-01
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Yahoo

Baird starts Array Technologies at Outperform on solar growth

2025-09-30
Investing.com -- Baird initiated coverage of Array Technologies with an Outperform rating and a price target of $11, saying the solar tracker maker stands to benefit from U.S. policy clarity, rising utility-scale solar demand, and its strong competitive position in a consolidating market.
Yahoo

Array (ARRY) Stock Is Up, What You Need To Know

2025-09-30
Shares of solar tracking systems manufacturer Array (NASDAQ:ARRY) jumped in the pre market session after analysts at both Deutsche Bank and Baird initiated coverage on the stock with favorable ratings.
Yahoo

3 Stocks With Estimated Discounts From 15.7% To 32.3% Offering Value Opportunities

2025-09-26
As U.S. stock indexes have recently experienced a series of declines, investors are closely monitoring economic indicators and inflation data to gauge market direction. In this environment, identifying undervalued stocks can offer potential opportunities for value-focused investors seeking to capitalize on estimated discounts ranging from 15.7% to 32.3%.
Yahoo

Why the Market Dipped But Array Technologies, Inc. (ARRY) Gained Today

2025-09-25
In the latest trading session, Array Technologies, Inc. (ARRY) closed at $8.17, marking a +2.51% move from the previous day.
Yahoo

1 Small-Cap Stock to Research Further and 2 We Question

2025-09-25
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Yahoo

Why Array (ARRY) Stock Is Up Today

2025-09-24
Shares of solar tracking systems manufacturer Array (NASDAQ:ARRY) jumped 5% in the afternoon session after positive macro developments for the solar industry, including a pledge from China's energy regulator to address price wars and a new clean energy investment program in New York.
Yahoo

Jefferies Lowers Its PT on Array Technologies, Inc. (ARRY) to $10, Maintains a ‘Buy’ Rating

2025-09-22
Array Technologies, Inc. (NASDAQ:ARRY) is one of the 11 Cheap Clean Energy Stocks to Buy Right Now. On September 16, 2025, Jefferies lowered its price target on Array Technologies, Inc. (NASDAQ:ARRY) from $13 to $10, maintaining a ‘Buy’ rating. The price revision reflects short-term margin pressure following the company’s acquisition of APA. The acquisition is […]
Yahoo